78190-11-1|1-[(Benzyloxy)carbonyl]-3-piperidinecarboxylic acid| Ambeed

Structure of 78190-11-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 78190-11-1 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 78190-11-1 ]

CAS No. :	78190-11-1
Formula :	C₁₄H₁₇NO₄
M.W :	263.29
SMILES Code :	O=C(C1CN(C(OCC2=CC=CC=C2)=O)CCC1)O
MDL No. :	MFCD02931282
InChI Key :	FFLPIVZNYJKKDM-UHFFFAOYSA-N
Pubchem ID :	234339

Safety of [ 78190-11-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 78190-11-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	19
Num. arom. heavy atoms	6
Fraction Csp3	0.43
Num. rotatable bonds	5
Num. H-bond acceptors	4.0
Num. H-bond donors	1.0
Molar Refractivity	73.2
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	66.84 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.18
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.64
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.59
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.57
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.28
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.65

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.41
Solubility	1.03 mg/ml ; 0.0039 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.66
Solubility	0.58 mg/ml ; 0.0022 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.36
Solubility	1.15 mg/ml ; 0.00436 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.74 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.73

Application In Synthesis of [ 78190-11-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 78190-11-1 ]

[ 78190-11-1 ] Synthesis Path-Downstream 1~35

1
[ 67-56-1 ]
[ 78190-11-1 ]
[ 174543-74-9 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

2
[ 501-53-1 ]
[ 498-95-3 ]
[ 78190-11-1 ]

Yield	Reaction Conditions	Operation in experiment
82%	With sodium hydroxide;	C. 1,3-Piperidinedicarboxylic acid, 1-(phenylmethyl)ester Benzyl chloroformate (4 mL) was added dropwise to a cooled (0-5 C.), stirred solution of piperidine-3-carboxylic acid (1.03 g, 8 mmol) in 1 N aqueous NaOH solution (25 mL). During the twenty minute addition, the pH was maintained between 8 and 9 by addition of 1 N NaOH solution. After addition was complete, the mixture was stirred cold for an additional hour, maintaining the pH thoughout this period. The reaction mixture was then extracted with ether (240 mL). The ether extracts were discarded and the aqueous layer was acidified with 1 N HCl solution. The acidified aqueous layer was then extracted with dichloromethane (240 mL). The combined extracts were dried over magnesium sulfate and concentrated in vacuo to give title acid as a viscous oil (1.73 g, 82%).
113%	In diethyl ether; water;	Example 437A N-Benzyloxycarbonyl nipecotic acid To a solution of nipecotic acid 10 g, 63.6 mmol) in 1 N NaOH (2.5 g in 64 mL water, 63.6 mmol) at 0 C. was alternately added benzyloxycarbonyl chloride (10.9 mL, 76.5 mmol) in diethyl ether (50 mL) and 1 N NaOH (5 g in 128 mL water, 127.2 mmol) in five portions. The reaction mixture was stirred at 0 C. for 2 hours, and at ambient temperature for 24 hours. Then this was made acidic with 10% HCl and the solid formed was filtered and dried (vacuum oven, 45 C.) to obtain the title compound (18.9 g, 113%). MS (ESI) m/e 264 (M+H)+.
		Example 153 A1-(benzyloxycarbonyl)piperidine-3-carboxylic acid; To the solution of piperidine-3-carboxylic acid (1.3 g, 10 mmol) in water (20 mL) was added sodium hydroxide (1.6 g, 40 mmol). Then benzyloxycarbonyl chloride (2.02 g, 12 mmol) was added dropwise at 0 C. The mixture was stirred at 0 C. for 2 h. The resulting mixture was treated with 5N hydrochloric acid to pH=6 and extracted with ethyl acetate, the solvent was removed under reduced pressure and dried in vacuum. 2.2 g of solid of 1-(benzyloxycarbonyl)piperidine-3-carboxylic acid was obtained. LC-MS (ESI) m/z: 264 (M+1)+.

		[1246] To a solution of nipecotic acid (10 g, 63.6 mmol) in 1 N NaOH (2.5 g in 64 mL water, 63.6 mmol) at 0 C. was alternately added benzyloxycarbonyl chloride (10.9 mL, 76.5 mmol) in diethyl ether (50 mL) and 1 N NaOH (5 g in 128 mL water, 127.2 mmol) in five portions. The reaction mixture was stirred at 0 C. for 2 h, and at ambient temperature for 24 h. Then this was made acidic with 10% HCl and the solid formed was filtered and dried (vacuum oven, 45 C.) to obtain the title compound (18.9 g, 113%). MS (ESI) m/e 264 (M+H)+.
		EXAMPLE 15 ()-BENZYL 3- (6-METHOXY-2-METHYL-1-OXO-4-PHENYL-1, 2-DIHYDROISOQUINOLIN-3-YL) PIPERIDINE-1- carboxylate; Step A: ()-L-F (BENZYLOXY) CARBONYLLPIPERIDINE-3-CARBOXYLIC ACID; To an ice cooled solution of nipecotic acid (10.0 g, 77.5 mmol), sodium hydroxide (3.4 g, 85 mmol), and tetrahydrofuran (50 ML) in water (100 ML) was added by simultaneous dropwise addition benzylchloroformate (13.3 ML, 93 mmol) in tetrahydrofuran (50 ML) and sodium hydroxide (3.4 g, 85 mmol) in water (50 mL). Warmed slowly to room temperature. After 24 hours tetrahydrofuran was removed in vacuo and the resulting aqueous mixture acidified with 3 N hydrochloric acid and extracted with dichloromethane (3X). The combined organic portions were dried with anhydrous magnesium sulfate. Filtration followed by evaporation of the filtrate in vacuo gave the titled COMPOUND. HNMR (CHCIS, 300MHZ) Q 7.45-7. 20 (m, 5H) ; 5.14 (m, 2H); 4.21 (br S, 1H) ; 3.96 (m, 1H), 3.15 (br s, 1H) ; 2.93 (m, 1H) ; 2.51 (m, 1H) ; 2.09 (m, 1H); 1.80-1. 60 (m, 2H); 1.50 (m, 1H) ppm
		To a stirred solution of 3-piperidine carboxylic acid (1.48 g, 11.5 mmol) and saturated sodium bicarbonate (40 mL) in tetrahydrofuran (40 mL) at 0 C. was added benzylchloroformate (2.05 g, 12.0 mmol). The mixture was stirred in an ice-bath for 3 h, and then at room temperature for 16 h. The mixture was then cooled to 0 C. and the pH was reduced to ca. 1.0 with 6 M HCl. The mixture was extracted three times with ethyl acetate. The combined extracts were dried with magnesium sulfate, filtered, and concentrated to provide 10.0 g of the title compound as a colorless oil.
		Step 1. 1-(Benzyloxycarbonyl)piperidine-3-carboxylic; A 500-mL 4-necked round-bottom flask was charged with a solution of NaOH (8 g, 198.00 mmol, 1.00 equiv, 99%) in H2O (200 mL). To this was added piperidine-3-carboxylic acid (25.8 g, 197.75 mmol, 1.00 equiv, 99%), in small portions at 0 C. Then, a solution of benzyl carbonochloridate (39.2 g, 227.48 mmol, 1.15 equiv, 99%) in Et2O (50 mL) was added at 0 C. over 40 minutes. Then a solution of NaOH (12 g, 1.50 equiv) in H2O (300 mL) was added drop wise with stirring at 0-10 C. The resulting solution was allowed to stir overnight at room temperature. The reaction progress was monitored by TLC (EtOAc/PE=1/1). The pH adjusted to 3 with 10% aqueous HCl. The resulting solution was extracted with ethyl acetate (3×500 mL). Combined organic layers were dried over anhydrous magnesium sulfate and concentrated on a rotary evaporator to afford 1-(benzyloxycarbonyl)piperidine-3-carboxylic acid (58 g) as white solid.
	With sodium hydroxide; In water; at 0 - 20℃;	Step 1: In a 100 ml three-necked flask, in a stream of nitrogen and under magnetic stirring the nipecotinic acid (3.7 g) was placed in solution in a 3N sodium hydroxide solution (30 ml). The solution was cooled over an ice bath to 0 C. Benzyl chloroformiate (5.8 ml) was added in fractions at 0 C. alternately with a 3N sodium hydroxide solution (9.3 ml) for a time of 45 min. After the addition time the reaction medium was pale yellow and the temperature 3 C. The ice bath was removed and the reaction medium left under stirring at ambient temperature overnight. The aqueous phase was then extracted once with ethyl ether, then acidified to pH 1 using a 3N hydrochloric acid solution. The acidified aqueous phase was extracted three times with ethyl ether. The ether extract phase was successively washed with 1N hydrochloric acid solution, then twice with saturated sodium chloride solution before being dried over magnesium sulphate, filtered then concentrated in vacuo. [0126] The yellow oil obtained (7.35 g, 98%) was used at the following step without any purification step.

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.
[2]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 397 - 416.
[3]Patent: US5583146,1996,A .
[4]Patent: US6878700,2005,B1 .
[5]Patent: US2009/197863,2009,A1 .Location in patent: Page/Page column 71.
[6]Patent: US2004/116518,2004,A1 .Location in patent: Page 117.
[7]Patent: WO2005/30726,2005,A1 .Location in patent: Page/Page column 20; 31.
[8]Patent: US2006/19975,2006,A1 .Location in patent: Page/Page column 21.
[9]Patent: US8080566,2011,B1 .Location in patent: Page/Page column 30.
[10]Patent: US2014/315950,2014,A1 .Location in patent: Paragraph 0125-0126.

3
[ 78190-11-1 ]
[ 216502-94-2 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; In dichloromethane; at 0 - 20℃;	Example 153 Bbenzyl-3-(chlorocarbonyl)piperidine-1-carboxylate; To a stirred solution of <strong>[78190-11-1]1-(benzyloxycarbonyl)piperidine-3-carboxylic acid</strong> (1.05 g, 4 mmol) in anhydrous dichloromethane (10 mL), thionyl chloride (0.573 g, 4.81 mmol) was added drop wise at 0 C. After the addition, the solution was stirred at room temperature overnight. Solvent was removed in vacuum to give benzyl-3-(chlorocarbonyl)piperidine-1-carboxylate.
	With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0 - 20℃; for 2h;	STEP B : ()-BENZYL-3- (CHLOROCARBONYL) PIPERIDINE-L-CARBOXYLATE; To an ice cooled methylene chloride solution of 1- [(Benzyloxy) carbonyl] piperidine-3-carboxylic acid (512 mg, 1.95 mmol) under nitrogen was added oxalyl chloride (0.185 mL, 1.95 mmol) and a few drops N, N-DIMETHYLFORMAMIDE. The reaction flask was warmed slowly to room temperature and after 2 hours the solvent was removed in vacuo. Toluene was added and removed in vacuo (2X) to give the title compound.

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 1577 - 1595.
[2]Bioorganic and Medicinal Chemistry,2005,vol. 13,p. 397 - 416.
[3]Patent: US2009/197863,2009,A1 .Location in patent: Page/Page column 71.
[4]Patent: WO2005/30726,2005,A1 .Location in patent: Page/Page column 20; 31.
[5]Organic Letters,2017,vol. 19,p. 2426 - 2429.

Yield	Reaction Conditions	Operation in experiment
18.0 g (68 mmol; 35%)		A. N-Cbz-nipecotic acid STR31 By substantially following the procedures of Example 1,A, 25.0 g (194 mmol) of nipecotic acid was protected with benzylchloroformate under basic conditions to afford 18.0 g (68 mmol; 35%) of analytically pure N-Cbz-nipecotic acid as a white solid. FD-MS, m/e 264 (MH+, 100). IR (KBr) 3092, 2950, 1732, 1649, 1449, 1273, 1155, 696 cm-1. Analytical Calculated for C14 H17 N1 O4: C 63.87, H 6.51, N 5.32 Found: C 63.98, H 6.58, N 5.36
18.0 g (68 mmol; 35%)		A N-Cbz-nipecotic acid STR54 By substantially following the procedures of Example 15, A, 25.0 g (194 mmol) of nipecotic acid was protected with benzylchloroformate under basic conditions to afford 18.0 g (68 mmol; 35%) of analytically pure N-Cbz-nipecotic acid as a white solid. FD-MS, m/e 264 (MH+, 100). IR (KBr) 3092, 2950, 1732, 1649, 1449, 1273, 1155, 696 cm-1. Analytical Calculated for C14 H17 N1 O4: C 63.87, H 6.51, N 5.32 Found: C 63.98, H 6.58, N 5.36

5
[ 78190-11-1 ]
(S)-3-{4-Methoxy-3-[(piperidine-3-carbonyl)-amino]-phenyl}-2-(2,2,2-trifluoro-acetylamino)-propionic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 1577 - 1595.

6
[ 78190-11-1 ]
(S)-3-{4-Methoxy-3-[(piperidine-3-carbonyl)-amino]-phenyl}-2-(2,2,2-trifluoro-acetylamino)-propionic acid tert-butyl ester [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 1577 - 1595.

7
[ 78190-11-1 ]
[ 216502-71-5 ]

References: [1]Bioorganic and Medicinal Chemistry,1998,vol. 6,p. 1577 - 1595.

8
[ 78190-11-1 ]
[ 174543-80-7 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

9
[ 78190-11-1 ]
[ 174543-79-4 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

10
[ 78190-11-1 ]
[ 174543-78-3 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

11
[ 78190-11-1 ]
[ 174543-81-8 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

12
[ 78190-11-1 ]
[ 174543-82-9 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 1297 - 1300.

13
[ 98946-18-0 ]
[ 78190-11-1 ]
[ 301180-04-1 ]

Yield	Reaction Conditions	Operation in experiment
96%	With boron trifluoride diethyl etherate; In tetrahydrofuran; at 20℃; for 18h;	[1247] A solution of Example A (18 g, 62 mmol). in THF (250 mL, 0.25 M) was treated with trichloroacetimidate (28 mL, 155 mmol) and BF3.Et2O (18 mL, 1 mL/g) at ambient temperature. After 18 h the reaction mixture was quenched with solid NaHCO3 followed by water and stirred vigorously. Then the solvent was removed, and partitioned with ethyl acetate (250 mL). The organic layer was separated and washed with brine (3×80 mL), dried (Na2SO4) and evaporated to dryness under reduced pressure to obtain the crude product. The title compound (19.2 g, 96%) was obtained by flash chromatography on silica gel eluting with 20% acetone:hexane. MS (ESI) m/e 320 (M+H)+.

References: [1]Patent: US2004/116518,2004,A1 .Location in patent: Page 117.

14
C₃₅H₃₈N₄O₃ [ No CAS ]
[ 78190-11-1 ]
piperidine-3-carboxylic acid[(2S,5S)-5-naphthalen-2-ylmethyl-3,6-dioxo-1-(4-phenoxy-benzyl)-piperazin-2-ylmethyl]-piperidin-4-ylmethyl-amide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Step 1: To the corresponding Cbz-protected product from general procedure G, step D (323 mg, 0.441 mmol), N-cbz-piperidin-3-ylcarboxylic acid (370 mg, 1.405 mmol), and TBTU (450 mg, 1.400 mmol) in THF (15 ml) is added at room temperature N-ethyldiisopropylamine (0.3 ml, 1.718 mmol) and the mixture is stirred at room temperature overnight and then heated to reflux for 8 h. Sat. aq. sodium bicarbonate (40 ml) is added, the mixture stirred for 15 min., and then extracted with ether (3 x 70 ml). The combined org. layers are dried over sodium sulfate, concentrated in vacuo, and the residue purified by flash chromatography (silica, dichloromethane/MeOH 20:1) to give a mixture of the 2 diastereoisomeric bis-Cbz-protected intermediates. Flash chromatography (silica, ethyl acetate/MeOH 100:0 - 50:1) afforded the 2 diastereoisomers (23 % and 16 %). ESI-MS: (M+H)+ = 942. Step 2: The 2-Cbz-protected diastereoisomers are submitted separately to hydrogenation in MeOH (20 ml) at 50 psi in the presence of Pd/C (10 %) at 50 C for 2 h. The catalyst is removed by filtration and the filtrate is concentrated in vacuo to give the product (41 % and 35 %). ESI-MS: (M+H)+ = 674

References: [1]Patent: WO2004/48345,2004,A2 .Location in patent: Page 133.

15
[ 17284-97-8 ]
[ 78190-11-1 ]
C₁₈H₂₀ClN₅O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 16h;	A mixture of <strong>[78190-11-1]1-[(benzyloxy)carbonyl]piperidine-3-carboxylic acid</strong> (2.44 g), 3-chloro-6-hydrazinopyridazine (1.34g), WSCD hydrochloride (2.13 g) and methylene chloride (60 ml) was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure and extracted with ethyl acetate. The extract was washed successively with water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resultant reside was combined with acetic acid (80 ml), stirred at 100C for 2 days, and then the solvent was distilled off under reduced pressure. The resultant crude crystals were washed with ethanol, and stirred with heating under reflux in piperidine (10 ml) for 3 hours. The reaction solution was concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: chloroform:methanol=97:3). The resultant colorless solids were combined with ethanol (40 ml) and 10% palladium-carbon (150 mg), and stirred under hydrogen atmosphere at room temperature for 6 hours, and then the catalyst was filtered off. The resultant filtrate was concentrated under reduced pressure to obtain 6-piperidin-1-yl-3-piperidin-3-yl-1,2,4-triazolo[4,3-b]pyridazine (1.18 g) as a colorless amorphous.

References: [1]Patent: EP1481977,2004,A1 .Location in patent: Page 11.

16
[ 78190-11-1 ]
[ 75-03-6 ]
[ 310454-53-6 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 5h;	Reference Example 25 A mixture of <strong>[78190-11-1]1-[(benzyloxy)carbonyl]-3-piperidinecarboxylic acid</strong> (20.0 g), iodoethane (14.2 g), potassium carbonate (15.7 g), and N,N-dimethylformamide (150 mL) was stirred at room temperature for 5 hours. The reaction solution was poured into water and extracted with ethyl acetate. The extracts were washed with water, dried and concentrated. The obtained residue was purified by silica gel column chromatography to obtain ethyl 1-[(benzyloxy)carbonyl]-3-piperidinecarboxylate (20.0 g). 1H-NMR (300 MHz, CDCl3) delta: 1.24 (3H, t, J=7.5 Hz), 1.45-1.74 (3H, m), 2.02-2.08 (1H, m), 2.42-2.48 (1H, m), 2.85-3.13 (2H, m), 3.95-4.02 (1H, m), 4.12 (2H, q, J=7.5 Hz), 4.18-4.30 (1H, m), 5.12 (2H, s), 7.27-7.36 (5H, m).

References: [1]Patent: EP1553074,2005,A1 .Location in patent: Page/Page column 41.

17
[ 5468-37-1 ]
[ 78190-11-1 ]
[ 874361-32-7 ]

Yield	Reaction Conditions	Operation in experiment
	With 1-propan-phosphonic acid anhydride; triethylamine; In tetrahydrofuran; ethyl acetate; at 20℃; for 16h;	A mixture of piperidine-1,3-dicarboxylic acid 1-benzyl ester (3.0 g, 11.4 mmol), triethylamine (4.62 g, 45.6 mmol), and 1-propanphosphonic acid anhydride (3.63 g, 11.4 mol, 6.80 mL of a 50% w/w solution in ethyl acetate) and 2 aminoacetophenone hydrochloride (1.96 g, 11.4 mmol) in THF (55 mL) was stirred at rt for 16 h. The mixture was then concentrated, and the residue was dissolved in CH2Cl2. The solution was washed with 1 M NaOH, dried through cotton, and concentrated. Silica gel chromatography eluding with 1:2 hexanes/ethyl acetate gave the title compound as a pale yellow solid.

References: [1]Patent: US2006/19975,2006,A1 .Location in patent: Page/Page column 21-22.

18
[ 27550-90-9 ]
isobutyl chioroformate [ No CAS ]
[ 6638-79-5 ]
[ 78190-11-1 ]
[ 405239-72-7 ]

Yield	Reaction Conditions	Operation in experiment
	In tetrahydrofuran;	To a cooled (-15 C. to -20 C.) and stirred solution of <strong>[78190-11-1]1-[(benzyloxy)carbonyl]-3-piperidinecarboxylic acid</strong> (4.0 g, 15.2 mmol) in dry THF (50 mL) including methylmorpholine (2 mL) was added dropwise a solution of isobutyl chioroformate (2.28 g, 16.7 mmol) in THF (10 mL). After the mixture was stirred at the same temperature for 20 min, a solution of N,O-dimethylhydroxylamine hydrochloride (1.63 g, 16.7 mmol) in THF (20 mL) including methylmorpholine (2 mL) was added. The reaction mixture was allowed to warm to room temperature, and then stirred for 16 hrs. The reaction mixture was concentrated under reduced pressure and partitioned between ethyl acetate and water. The separated organic phase was washed with 1N HCl, saturated NaHCO3, and brine, successively. The organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure to give benzyl 3-[methoxy(methyl)amino]carbonyl)-1-piperidinecarboxylate as a colorless oil (4.7 g, yield; quant.).

References: [1]Patent: US6562811,2003,B1 .

19
[ 948-65-2 ]
[ 79-37-8 ]
[ 925-90-6 ]
[ 78190-11-1 ]
[ 256446-54-5 ]

Yield	Reaction Conditions	Operation in experiment
15.6 g (35.6 mmol; 63%)	With ammonium chloride;SiO2; In diethyl ether; dichloromethane; ethyl acetate; N,N-dimethyl-formamide; toluene; benzene;	A. 3-(2-Phenyl-1H-indole-3-carbonyl)piperidine-1-carboxylic acid benzyl ester A solution of 14.8 g (56.3 mmol) of N-benzyloxycarbonylnipecotic acid in anhydrous dichloromethane (100 ml) under an atmosphere of nitrogen was treated with oxalyl chloride (7.4 ml, 84.4 mmol) followed by 2 drops of N,N-dimethylformamide. The reaction mixture was stirred at room temperature for 90 min at which time the dichloromethane was evaporated in vacuo. The residue was dissolved in anhydrous toluene (75 ml) and the resulting solution evaporated in vacuo. The residue was dissolved in anhydrous benzene (50 ml) to give Solution A. A solution of 21.7 g (113 mmol) of 2-phenylindole in anhydrous benzene (250 ml) under an atmosphere of nitrogen was added using a cannula to a solution of ethylmagnesium bromide (37.5 ml of a 3M solution in diethyl ether, 113 mmol) and the resulting mixture stirred at room temperature for 15 min to give Solution B. Solution A was added in one portion to rapidly stirred solution B and the resulting mixture stirred at room temperature for 30 min. The reaction was quenched by the addition of saturated ammonium chloride solution (200 ml). The organic layer was separated, dried over MgSO4 and evaporated in vacuo. The residue was purified by flash chromatography (SiO2; 10% EtOAc in hexanes then 20% EtOAc in hexanes) to afford 15.6 g (35.6 mmol; 63%) of 3-(2-phenyl-1H-indole-3-carbonyl)piperidine-1-carboxylic acid benzyl ester as a clear oil. deltaH (360 MHz; CDCl3) 0.91-1.07 (1H, m, aliphatic), 1.50-1.65 (2H, m, aliphatics), 1.88-1.96 (1H, m, aliphatic), 2.58-2.82 (2H, m, aliphatics), 2.86-3.08 (1H, m, aliphatic), 3.92-4.06 (1H, m, aliphatic), 4.08-4.17 (1H, m, aliphatic), 5.05 (2H, d, J 3.8, PhCH2), 7.24-7.52 (13H, m, aromatics), 8.24-8.30 (1H, m, aromatic), 8.75 (1H, br s, NH); m/z (ES+) 439 (M++H, 100%).

References: [1]Patent: US6479480,2002,B1 .

20
[ 501-53-1 ]
[ 118156-93-7 ]
[ 78190-11-1 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In 1,4-dioxane; hexane;	To a cooled (0 C.) and stirred solution of nipecotinic acid (3.0 g, 23.3 mmol) in 1,4-dioxane (12 mL) was added 2N NaOH solution (24.0 mL, 48.0 mmol) followed by a solution of benzyl chloroformate (3.96 g, 23.2 mmol) in 1,4-dioxane (12 mL). The reaction mixture was allowed to warm to room temperature, and the stirring was continued for 3 hrs. The mixture was concentrated under reduced pressure. The residue was diluted with water and acidified with 1H HCl (pH 3-4). The mixture was extracted with ethyl acetate, and the separated organic phase was washed with brine, dried over Na2SO4, filtered, and evaporated. The resulting white solid was suspended in hexane, collected by filtration, washed with hexane, and dried under reduced pressure to give 1-[(benzyloxy)carbonyl]-3-piperidinecarboxylic acid as a white solid (4.4 g, yield; 71%).

References: [1]Patent: US6562811,2003,B1 .

21
[ 702692-02-2 ]
[ 78190-11-1 ]
C₅₇H₅₉N₅O₈ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
16%	With benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at 20℃; for 8h;Heating / reflux;	Step 1: To the corresponding Cbz-protected product from general procedure G, step D (323 mg, 0.441 mmol), N-Cbz-piperidin-3-yl carboxylic acid (370 mg, 1.405 mmol), and TBTU (450 mg, 1.400 mmol) in THF (15 ml) is added at room temperature N-ethyldiisopropylamine (0.3 ml, 1.718 mmol) and the mixture is stirred at room temperature overnight and then heated to reflux for 8 h. Sat. aq. sodium bicarbonate (40 ml) is added, the mixture stirred for 15 min., and then extracted with ether (3×70 ml). The combined org. layers are dried over sodium sulfate, concentrated in vacuo, and the residue purified by flash chromatography (silica, dichloromethane/MeOH 20:1) to give a mixture of the 2 diastereoisomeric bis-Cbz-protected intermediates. Flash chromatography (silica, ethyl acetate/MeOH 100:0?50:1) afforded the 2 diastereoisomers (23% and 16%). ESI-MS: (M+H)+=942.

References: [1]Patent: US2007/185128,2007,A1 .Location in patent: Page/Page column 62.

22
3-carbamoylbenzene-1,2-diaminium dichloride [ No CAS ]
[ 78190-11-1 ]
C₂₁H₂₄N₄O₄ [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2008,vol. 16,p. 6965 - 6975.

23
[ 78190-11-1 ]
[ 19961-27-4 ]
[ 953821-03-9 ]

Yield	Reaction Conditions	Operation in experiment
100%		Reference Example 48 benzyl 3-[ethyl(isopropyl)amino]carbonyl}piperidine-1-carboxylate To a solution of <strong>[78190-11-1]1-[(benzyloxy)carbonyl]piperidine-3-carboxylic acid</strong> (3.00 g, 11.4 mmol) and DMF (2 drops) in THF (60 mL) was added oxalyl chloride (1.47 mL, 17.1 mmol) under ice-cooling, and the mixture was concentrated under reduced pressure after 1 hr. The obtained residue was dissolved in THF (60 mL), ethylisopropylamine (4.14 mL, 34.2 mmol) was added under ice-cooling, and the mixture was stirred for 30 min. The solvent was evaporated under reduced pressure, ethyl acetate was added to the residue, and the mixture was washed with 1N hydrochloric acid, 10% potassium carbonate and saturated brine, and dried over anhydrous sodium sulfate. The solution was purified by asic silica gel to give the title compound (3.79 g, quantitative). The compound was used for Reference Example 49 without purification.

References: [1]Patent: EP2009011,2008,A1 .Location in patent: Page/Page column 39; 40.

24
[ 78190-11-1 ]
[ 74-89-5 ]
[ 1161364-24-4 ]

Yield	Reaction Conditions	Operation in experiment
61%	With dmap; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 48h;	Preparation of Intermediates 7, 8, and 9Step 1A mixture of an appropriate amine or (1.0 mmol), N-(benzyloxycarbonyl)nipecotic acid (1.0 mmol), HBTU (1.0 mmol), a catalytic amount of 4-dimethylaminopyridine (DMAP), iV-ethyl- diisopropylethylamine (1.25 mmol), and dry dichloromethane (2 mL) was stirred at room temperature for two days. The solvent was removed under reduced pressure. EtOAc (25 mL) was added and the organic phase was washed with 5 % aqueous citric acid, saturated aqueous <n="67"/>NaHCO3 solution, and brine. After drying (MgSO4), the solvent was removed under reduced pressure. The desired Z-protected nipecotamide derivative was purified by preparative TLC, flash chromatography, or preparative HPLC.Methylamine and ethylamine were applied as 2 M solutions in THF. N-(Benzyloxycarbonyl)- nipecotic acid was commercially available.Benzyl S-Cmethylcarbamoy^piperidine-l-carboxylate: Yield 61 %. 1H NMR (CDCl3, 300 MHz): delta = 1.34-1.53 (m, 1 H), 1.57-1.94 (m, 3 H), 2.25 (m, 1 H, -COCH[CH2J2), 2.73 (d, J= 4.8 Hz, 3 H, -NHCH3), 3.00 (m, 1 H), 3.16 (m, 1 H), 3.91 (m, 1 H), 4.03 (m, 1 H), 5.09 (d, J= 12.5 Hz, 1 H, =NCH2CO), 5.14 (d, J = 12.5 Hz, 1 H, =NCH2CO-), 6.03 (s, br., 1 H, NH), 7.24-7.39 (m, 5 H, Ph). Piperidine ring proton signals were broad and not well resolved.Benzyl 3-(ethylcarbamoyl)piperidine-l-carboxylate: Yield 54 %. 1H NMR (CDCl3, 300 MHz): delta = 1.07 (t, J= 7.2 Hz, 3 H, -CH2CH3), 1.34-1.52 (m, 1 H), 1.57-1.93 (m, 3 H), 2.22 (m, 1 H, -COCH[CH2J2), 3.00 (m, 1 H), 3.16 (m, 1 H), 3.21 (q, J = 7.2 Hz, 1 H, -CH2CH3), 3.23 (q, J= 7.2 Hz, 1 H, -CH2CH3), 3.89 (m, 1 H), 4.02 (m, 1 H), 5.09 (d, br., J= 12.5 Hz, 1 H, =NCH2CO), 5.13 (d, br., J= 12.5 Hz, 1 H, =NCH2CO-), 6.01 (s, br., 1 H, NH), 7.24-7.39 (m, 5 H, Ph). Piperidine ring proton signals were broad and not well resolved.Benzyl 3-(pyrrolidine-l-carbonyl)piperidine-l-carboxylate: Yield 60 %. 1H NMR (CDCl3, 300 MHz): delta = 1.37-1.58 (m, 1 H), 1.64-2.02 (m, 7 H), 2.49 (m, 1 H, -COCH[CH2J2), 2.79 (m, 1 H), 2.95 (m, 1 H), 3.28-3.66 (m, 4 H), 4.20 (m, 2 H), 5.11 (d, J = 12.3 Hz, 1 H, <n="68"/>=NCH2CO), 5.15 (d, J= 12.3 Hz, 1 H, =NCH2CO-), 7.27-7.41 (m, 5 H, Ph). Piperidine ring proton signals were broad and not well resolved.

References: [1]Patent: WO2009/77844,2009,A2 .Location in patent: Page/Page column 65-66.

25
[ 117326-21-3 ]
[ 124-46-9 ]
[ 78190-11-1 ]
[ 688782-61-8 ]

References: [1]Patent: WO2004/39796,2004,A1 .Location in patent: Page/Page column 96-97.

26
[ 110-89-4 ]
[ 17284-97-8 ]
[ 78190-11-1 ]
[ 596824-17-8 ]

Yield	Reaction Conditions	Operation in experiment
		A mixture of <strong>[78190-11-1]1-[(benzyloxy)carbonyl]piperidine-3-carboxylic acid</strong> (2.44 g), 3-chloro-6-hydrazinopyridazine (1.34g), WSCD hydrochloride (2.13 g) and methylene chloride (60 ml) was stirred at room temperature for 16 hours. The reaction solution was concentrated under a reduced pressure and extracted with ethyl acetate. The extract was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under a reduced pressure. The resultant reside was combined with acetic acid (80 ml), stirred at 110C for 2 days, and then the solvent was evaporated under a reduced pressure. The resultant crude crystals were washed with ethanol and stirred with heating under reflux in piperidine (10 ml) for 3 hours. The reaction solution was concentrated under a reduced pressure and purified by a silica gel column chromatography (eluent: chloroform:methanol = 97:3). The resultant colorless solids were combined with ethanol (40 ml) and 10% palladium-carbon (150 mg) and stirred under an atmosphere of hydrogen at room temperature for 6 hours, and then the catalyst was removed by filtration. The resultant filtrate was concentrated under a reduced pressure to obtain 6-piperidin-1-yl-3-piperidin-3-yl-1,2,4-triazolo[4,3-b]pyridazine (1.18 g) as a colorless amorphous substance.

References: [1]Patent: EP1640010,2006,A1 .Location in patent: Page/Page column 18.

27
[ 186581-53-3 ]
[ 78190-11-1 ]
[ 1271809-00-7 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of acid 17.1 (6.1 g) in THF (30 mL) cooled to -20 C was added NMM (2.55 mL) followed by the dropwise addition of IBCF (3.04 mL). The resulting mixture was allowed to warm to 0 C and stirred for lhr. The resulting suspension was filtered, and the filtrate was collected, cooled to 0 C, and treated with a CH2 2 solution in ether (50 mL). The above solution of CH2 2 in ether was prepared from 13.7 g of l -methyl-3-nitro- nitrosoguanidine and 12.3 g of KOH in mixture of 100 mL of H2O and ether (1 : 1). The mixture was stirred at RT for 12 h and quenched by the dropwise addition of 4.0 N HC1 in dioxane (20 mL) at 0 C. The mixture was further stirred for 1 h. The organic phase was washed with H2O, brine and dried (MgSC^), filtered and concentrated in vacuo. The resulting residue was purified by column chromatography (gradient 30 % EtOAc in hexane) to give compound 17.3 (4.5 g).

References: [1]Patent: WO2011/29046,2011,A1 .Location in patent: Page/Page column 118; 119.

28
[ 78190-11-1 ]
[ 1271802-71-1 ]

References: [1]Patent: WO2011/29046,2011,A1 .

29
[ 78190-11-1 ]
[ 1260676-04-7 ]

References: [1]Patent: WO2011/29046,2011,A1 .

30
[ 78190-11-1 ]
[ 1271809-02-9 ]

References: [1]Patent: WO2011/29046,2011,A1 .

31
[ 78190-11-1 ]
[ 1271809-04-1 ]

References: [1]Patent: WO2011/29046,2011,A1 .

32
[ 78190-11-1 ]
[ 1271809-06-3 ]

References: [1]Patent: WO2011/29046,2011,A1 .

33
[ 6638-79-5 ]
[ 78190-11-1 ]
[ 405239-72-7 ]

Yield	Reaction Conditions	Operation in experiment
93%		To a solution of 1-benzyloxycarbonylpiperidinc-3-carboxylic acid (10 g, 43.6 mmol) in THF(100 mL) at 0 C was addcd 1,V-carbonyldiimidazole (38.57 g, 52.3 mmol). The mixture wasstirred at 0 C for 1 h. Triethylamine (7.13 g, 69.8 mmol) was added followed by Nmethoxymethanamine hydrochloride (6.38 g, 65.4 mmol). The mixture was allowed to warm to room temperature and stirred for 16 h. The mixture was diluted with EtOAc, washed with 0.5 N HC1, sat. NaHCO3, and brine. The organic layer was dried (Na2SO4), filtered and concentrated. The crude product was purified by silica flash chromatography (0-30% EtOAc/heptane) to givethe title compound (11.03 g, 93% yield) as a colorless oil. ?H NMR (400 MHz, Chloroform-d)7.40 -7.28 (m, 5H), 5.20-5.07 (m, 211), 4.15 (d,J 34.48 Hz, 2H), 3.66 (ci, Jr 38.49 Hz, 3H),3.16 (s, 3H), 2.94 (d,J= 12.21 Hz, 111), 1.99- 1,88 (m, 111), 1.79-1.62 (m, 2H), 1.57 (s, 211).LCMS (EST) mz 307.2 [M+Hj.
83%	With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In dichloromethane; at 2 - 20℃;	Step 2. Benzyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate; A 1000-mL 3-necked round-bottom flask was charged with a solution of N-methoxymethan amine hydrochloride (21.45 g, 217.7 mmol, 1.10 equiv, 99%) in dichloromethane (DCM) (250 mL). To the mixture was added Et3N (22.22 g, 217.80 mmol, 1.10 equiv, 99%) at 0-10 C., followed by addition <strong>[78190-11-1]1-(benzyloxycarbonyl)piperidine-3-carboxylic acid</strong> (58 g, 220.3 mmol, 1.00 equiv) in dichloromethane (150 mL) drop wise at 2 C. over 2 hr period. To this mixture was added EDC.HCl (42.02 g, 217.80 mmol, 1.10 equiv, 99%) in several batches while maintaining the temperature below 5 C. The resulting solution was allowed to stir at room temperature overnight. The progress was monitored by TLC (EtOAc: PE=1:1). Upon completion, the reaction was then quenched by the addition of water (500 mL). The resulting mixture was then extracted with dichloromethane (2×500 mL). Combined organic layers were dried over anhydrous magnesium sulfate and concentrated on a rotary evaporator. The resulting residue was purified by a silica gel column chromatography eluted with ethyl acetate/petroleum ether (1:10) affording benzyl 3-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate as a white syrup (57 g, 83%).

References: [1]Patent: WO2016/112284,2016,A1 .Location in patent: Page/Page column 78.
[2]Patent: US8080566,2011,B1 .Location in patent: Page/Page column 30.

34
[ 78190-11-1 ]
[ 502639-39-6 ]

References: [1]Patent: US8080566,2011,B1 .

35
[ 78190-11-1 ]
[ 1352654-67-1 ]

References: [1]Patent: US8080566,2011,B1 .

Historical Records

Technical Information

• Acyl Group Substitution • Arndt-Eistert Homologation • Chan-Lam Coupling Reaction • Complex Metal Hydride Reductions • Hunsdiecker-Borodin Reaction • Hydride Reductions • Lawesson's Reagent • Passerini Reaction • Preparation of Amines • Preparation of Carboxylic Acids • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Reactions of Carboxylic Acids • Schmidt Reaction • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • Ugi Reaction

Related Functional Groups of
[ 78190-11-1 ]

Aryls

A133393 [160706-62-7]

(R)-1-((Benzyloxy)carbonyl)piperidine-3-carboxylic acid

Similarity: 1.00

A229668 [310454-53-6]

1-Benzyl 3-ethyl piperidine-1,3-dicarboxylate

Similarity: 0.97

A204387 [10314-98-4]

N-Cbz-4-Piperidinecarboxylic acid

Similarity: 0.96

A111441 [154548-45-5]

1-Benzyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate

Similarity: 0.94

A320217 [138163-07-2]

1-Benzyl 4-methyl piperidine-1,4-dicarboxylate

Similarity: 0.94

Amides

A133393 [160706-62-7]

(R)-1-((Benzyloxy)carbonyl)piperidine-3-carboxylic acid

Similarity: 1.00

A229668 [310454-53-6]

1-Benzyl 3-ethyl piperidine-1,3-dicarboxylate

Similarity: 0.97

A204387 [10314-98-4]

N-Cbz-4-Piperidinecarboxylic acid

Similarity: 0.96

A111441 [154548-45-5]

1-Benzyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate

Similarity: 0.94

A320217 [138163-07-2]

1-Benzyl 4-methyl piperidine-1,4-dicarboxylate

Similarity: 0.94

Carboxylic Acids

A133393 [160706-62-7]

(R)-1-((Benzyloxy)carbonyl)piperidine-3-carboxylic acid

Similarity: 1.00

A204387 [10314-98-4]

N-Cbz-4-Piperidinecarboxylic acid

Similarity: 0.96

A111441 [154548-45-5]

1-Benzyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate

Similarity: 0.94

A130529 [63845-28-3]

2-(1-((Benzyloxy)carbonyl)piperidin-4-yl)acetic acid

Similarity: 0.93

A177627 [63845-33-0]

3-(1-((Benzyloxy)carbonyl)piperidin-4-yl)propanoic acid

Similarity: 0.93

Related Parent Nucleus of
[ 78190-11-1 ]

Piperidines

A133393 [160706-62-7]

(R)-1-((Benzyloxy)carbonyl)piperidine-3-carboxylic acid

Similarity: 1.00

A229668 [310454-53-6]

1-Benzyl 3-ethyl piperidine-1,3-dicarboxylate

Similarity: 0.97

A204387 [10314-98-4]

N-Cbz-4-Piperidinecarboxylic acid

Similarity: 0.96

A111441 [154548-45-5]

1-Benzyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate

Similarity: 0.94

A320217 [138163-07-2]

1-Benzyl 4-methyl piperidine-1,4-dicarboxylate

Similarity: 0.94

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 78190-11-1

{[proInfo.proName]}

CAS No.: 78190-11-1

Alternative Products

Product Details of [ 78190-11-1 ]

Safety of [ 78190-11-1 ]

Computational Chemistry of [ 78190-11-1 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 78190-11-1 ]

[ 78190-11-1 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 78190-11-1 ]

Aryls

Amides

Carboxylic Acids

Related Parent Nucleus of
[ 78190-11-1 ]

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

{[proInfo.proName]}

CAS No.: 78190-11-1

{[proInfo.proName]}

CAS No.: 78190-11-1

Alternative Products

Product Details of [ 78190-11-1 ]

Safety of [ 78190-11-1 ]

Computational Chemistry of [ 78190-11-1 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 78190-11-1 ]

[ 78190-11-1 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of [ 78190-11-1 ]

Aryls

Amides

Carboxylic Acids

Related Parent Nucleus of [ 78190-11-1 ]

Piperidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Related Functional Groups of
[ 78190-11-1 ]

Related Parent Nucleus of
[ 78190-11-1 ]